Results 171 to 180 of about 130,782 (308)

Cardiotoxicity of BRAF/MEK Inhibitors

open access: yesJACC: CardioOncology, 2023
Claire Glen   +7 more
openaire   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia   +6 more
wiley   +1 more source

Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. [PDF]

open access: yesPLoS One
Tomita Y   +19 more
europepmc   +1 more source

Clinical and Genetic Landscape of Glioblastoma, IDH‐Wildtype With FGFR Gene Family Alterations

open access: yesCancer Science, EarlyView.
We analyzed 1076 cases of glioblastoma, IDH‐wildtype (GBM, IDH‐wt) using the C‐CAT genomic database to clarify the clinical and genetic features of FGFR alterations. FGFR::TACC fusions and FGFR1 mutations were identified in distinct subsets and were associated with unique co‐mutation patterns.
Yasuhito Kegoya   +9 more
wiley   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

open access: yesCancer Science, EarlyView.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda   +3 more
wiley   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer   +11 more
wiley   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy